(NASDAQ: AFFX) today announced the expansion of its license agreement with Siemens Healthcare Diagnostics for the company’s branched DNA (bDNA) technology whereby Affymetrix is the exclusive licensee ...
SANTA CLARA, Calif. & SAN DIEGO--(BUSINESS WIRE)--Affymetrix Inc. (NASDAQ:AFFX) and Reveal Biosciences LLC, an advanced tissue technologies company, today announced a partnership agreement through ...
Partnership will expand use of assay into pathology and cancer research markets. Affymetrix and the Massachusetts General Hospital (MGH) inked a collaboration and licensing agreement to co-develop ...
Technology combines ScreenCell’s isolation devices with Affymetrix’ QuantiGene ViewRNA assay. Affymetrix signed a worldwide distribution agreement for ScreenCell’s isolation devices and dilution ...
Global genetic products developer and manufacturer Affymetrix, Inc. (AFFX) recently announced a world-wide collaboration with Leica Microsystems, a leading manufacturer of microscopes and other ...
Affymetrix Inc., a pioneer in creating breakthrough tools that are driving the genomic revolution, and Leica Microsystems, a world leader in microscopes and scientific instruments, has signed a ...
Combination of ScreenCell's isolation devices and Affymetrix' QuantiGene(R) ViewRNA ISH technology enables easy, accessible, sensitive, multiplex, low-cost system to enumerate and characterize CTCs ...
Affymetrix Inc. and Reveal Biosciences LLC, an advanced tissue technologies company, announced a partnership agreement through which Reveal will use Affymetrix ViewRNA ISH products for tissue samples ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results